QualityDipStocks / Health Care · Ophthalmic Goods
The Cooper Companies COO
Outside our quality screen, so we don’t track its dips. It’s 29% below its 52-week high.
Outside our quality screen, trading below our fair value estimate, 6% over its Market Value.
- Fair value est.
- $70.93+19%
- Market Value
- $56.05price +6%
- Off 52-wk high
- −29%
- Risk vs market
- Lowbeta 0.44
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $59.55
- 52-wk lowlowest close, 1 year$53.27−10.5%
- Market Valueavg paid since Sep 9$56.05−5.9%
- PriceFri Oct 30 close$59.55you are here
- Fair value est.base case$70.93+19.1%
- 52-wk highhighest close, 1 year$84.32+41.6%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 7.3% ±2 points. Bear = 10.5% and 5.3%; bull = 8.5% and 9.3% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, COO’s free cash flow would need to grow about 4% a year for five years; our estimate uses 7%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much COO moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.44
- Volatility
- 32% vs 13% SPY
- Correlation SPY
- 0.18
- Correlation QQQ
- 0.01
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $70.93, 19% above the price.
Cash returnsFree cash flow grew 65% over the last 12 months vs the 12 months before.
ValuationP/E of 20.2× vs a 29.2× median for the 86 Health Care companies we cover.
ValuationFree-cash-flow yield of 5.9% (price / FCF 17.0×): $678M of free cash in the last 12 months.
Cash returnsShare count down 3.3% in a year: $644M of buybacks over 12 months.
Top bearish points 5 of 5
ProfitabilityReturn on invested capital of 5%, below the 9.5% discount rate our DCF uses.
ProfitabilityReturn on equity is only 7% over the last 12 months.
GrowthDiluted EPS fell 4.6% in the last fiscal year, below the 7.3% median for the 74 Health Care companies we cover.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
ValuationTrades 6.2% above its Market Value of $56.05, the average price paid since the Sep 9 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on The Cooper Companies in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Health Care
All fundamentals
P/E 20.2 · FCF yield 5.9% · ROE 7%
Valuation
- P/E
- 20.2×Health Care median 29.2×
- Price / FCF
- 17.0×
- FCF yield
- 5.9%
- EV / EBITDA
- 15.0×
- Price / sales
- 2.72×
- Price / book
- 1.38×
- Market cap
- $11.5Bprice × diluted shares
- Enterprise value
- $13.9B
Growth
- Revenue, 12 months
- $4.2B
- Sales growth, 12 months
- +4.7%vs the 12 months before
- Sales growth, 3 yrs
- +7.3%/yrfrom FY2022
- Diluted EPS, 12 months
- $2.91
- EPS growth, last FY
- −4.6%
- Net income, 12 months
- $570M
- Net income growth
- +40%12 months vs before
Profitability
- Gross margin
- 65.9%
- Operating margin
- 12.8%
- Net margin
- 13.5%
- FCF margin
- 16.0%
- Return on equity
- 7%
- Return on invested capital
- 5%
Balance sheet
- Cash & short-term inv.
- $155M
- Total debt
- $2.5B
- Net cash
- −$2.4B
- Debt / equity
- 0.31×
- Interest coverage
- 6.1×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $678M
- FCF growth, 12 months
- +65%
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $644M5.6% of market cap
- Share count, 1 year
- −3.3%diluted shares vs a year ago
- Stock-based comp
- $66M
Trailing 12 months to Jul 31, 2026; balance sheet at Jul 31, 2026. From The Cooper Companies’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $70.93 · MV $56.05 · FCF value $69.91
Assumes 7.3% growth for 5 years (revenue grew 7.3% a year FY22–FY25), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $3.51 a share (trailing 12 months to Jul 31, 2026), from the 10-Q filed Sep 9, 2026. Net debt $2.4B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 52 · 5 days −2.7%
The business
FCF $0.5B · Sales +1%
- Free cash flow, 12 months$0.5B
- Free-cash-flow yield4.7%
- Free-cash-flow margin13%
- Gross margin66%
- Operating margin21%
- Return on invested capital6%
- Return on equity7%
- Sales growth (latest quarter vs year-ago quarter)+1%
- Net debt / EBITDA2.8×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
COO is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.